Australia markets closed

Sorrento Therapeutics, Inc. (SRNE)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.6200+0.0800 (+5.19%)
At close: 04:00PM EDT
1.6000 -0.02 (-1.23%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.5400
Open1.5500
Bid1.6100 x 45100
Ask1.6200 x 1000
Day's range1.5039 - 1.6300
52-week range1.1500 - 11.0700
Volume9,238,933
Avg. volume9,485,547
Market cap630.092M
Beta (5Y monthly)2.43
PE ratio (TTM)N/A
EPS (TTM)-1.5270
Earnings date11 May 2020
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est21.00
  • Zacks

    Evogene (EVGN) Reports Q1 Loss, Lags Revenue Estimates

    Evogene (EVGN) delivered earnings and revenue surprises of -42.86% and 46.14%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Scilex, a Sorrento Company, Announces Initiation of a Phase 2 Study to Evaluate the Safety and Efficacy of SP-103 in Subjects with Acute Low Back Pain

    Dosing of the first subject in a Phase 2, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the safety and efficacy of SP-103 (lidocaine topical system) 5.4% in subjects with moderate to severe acute lower back pain (LBP). The trial will enroll 80 patients with acute lower back pain.SP-103 is a pharmacologically validated drug candidate and has the potential as a best-in-class agent of pain treatment for low back pain without the limitations of current t

  • GlobeNewswire

    Sorrento Therapeutics, Inc. Appoints Former Roche Executive Tammy Reilly to the Board of Directors

    SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc (Nasdaq: SRNE, “Sorrento”), a commercial and clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies and diagnostics, announced today the appointment of former Roche Laboratories executive, Tammy Reilly, to Sorrento’s board of directors. Ms. Reilly brings more than 30 years of life science, big pharma and operating leadership experience within healthcare therapeutics, consumer m